Drugs / Methylone
Methylone
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06303648 | Mar 2024 → Jul 2025 | post-traumatic stress disorder | Transcend Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05488171 | Dec 2021 → Jul 2022 | substance-related disorder | Germans Trias i Pujol Hospital | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05741710 | Mar 2023 → Feb 2025 | post-traumatic stress disorder | Transcend Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06215261 | Apr 2024 → Sep 2025 | post-traumatic stress disorder | Transcend Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT06237426 | Mar 2024 → Oct 2025 | post-traumatic stress disorder | Transcend Therapeutics | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07670702 | Jun 2026 → Dec 2028 expected | post-traumatic stress disorder | Transcend Therapeutics | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT07456696 | Apr 2026 → Dec 2027 expected | post-traumatic stress disorder | Transcend Therapeutics | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-27 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Pharmaceutical to Acquire Transcend Therapeutics- Expands Otsuka portfolio in psychiatric and neurological fields and aims to accelerate development of Transcend’s portfolio, including the TSND-201 program for post-traumatic stress disorder (PTSD) - otsuka.co.jp ↗ |
| 2026-03-27 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Pharmaceutical to Acquire Transcend Therapeutics - Expands Otsuka portfolio in psychiatric and neurological fields and aims to accelerate development of Transcend’s portfolio, including the TSND-201 program for post-traumatic stress disorder (PTSD) otsuka-us.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Methylone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06237426 ↗ |
| Known as | .beta.k-mdma | ChEMBL registry synonym — accepted as the source's own label CHEMBL3604010 ↗ |
| Known as | J899.632F | ChEMBL registry synonym — accepted as the source's own label CHEMBL3604010 ↗ |
| Known as | M1 (psychedelic) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3604010 ↗ |
| Known as | Methylenedioxymethcathinone | ChEMBL registry synonym — accepted as the source's own label CHEMBL3604010 ↗ |
| Known as | TSND-201 | “TSND-201 (methylone) is a highly selective, rapid-acting neuroplastogen” PMID 41706459 ↗ May 2026 |
| Modality | Other / unclassified | “Methylone is a synthetic cathinone” NCT05488171 ↗ |
| Route | Oral | “Single oral dose of 200 mg of methylone.” NCT05488171 ↗ |